Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL762285 | 0.95 | MEN1 (0.30) | LMNAMEN1ABCC4PKMPTGS1 | |
| SCHEMBL12734253 | 0.89 | — | — | |
| SCHEMBL16091822 | 0.88 | HTR3A (0.32) | LMNAMEN1ABCC4PKMPTGS1 | |
| SCHEMBL12055755 | 0.86 | HTR3A (0.35) | LMNAMEN1ABCC4PKMPTGS1 | |
| SCHEMBL761454 | 0.85 | — | — | |
| SCHEMBL10072571 | 0.85 | LMNA (0.34) | LMNAMEN1ABCC4PKMPTGS1 | |
| SCHEMBL12458892 | 0.85 | EPHA2 (0.35) | LMNAMEN1ABCC4PKMPTGS1 | |
| SCHEMBL19225906 | 0.84 | JAK2 (0.36) | LMNAMEN1ABCC4PKMPTGS1 | |
| SCHEMBL761081 | 0.82 | LMNA (0.38) | LMNAMEN1ABCC4PKMPTGS1 | |
| SCHEMBL12458625 | 0.80 | EPHA2 (0.35) | LMNAMEN1ABCC4PKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138202-B2 | Stable SNS-595 compositions and methods of preparation | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110086876-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | SUNESIS PHARMACEUTICALS, INC. | 2011-04-14 | — | — | US | disclosed |
| US-20110082169-A1 | Stable SNS-595 Compositions and Methods of Preparation | SUNESIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082169-A1 | Stable SNS-595 Compositions and Methods of Preparation | NES, NCDN, NCL | LMNA 410/4885MEN1 1500/4885ABCC4 4088/4885 |
| US-20110086876-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | NES, NCDN, NCL | LMNA 410/4885MEN1 1500/4885ABCC4 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.